Sat, 05/20/2023 - 12:00pm
CME PROGRAM PLANNER:
Minhchau T. Nguyen, MD
Nelson Chiang, MD
Physicians, NPs, PAs - HBS
1. Recognize that SGLT2 inhibitors block reabsorption of glucose in the kidneys and dilate the afferent arterioles in the kidney.
2. Recognize that blocking SGLT2 decreased HbA1c by 0.5-1.15 and did not cause hypoglycemia.
3. Recognize that SGLT2 inhibitor trials showed decreased cardiac events (myocardial infarction, stroke, and death from cardiac causes) along with decreased hospitalization from congestive heart failure.
4. Recognize that SGLT2 inhibitors protect the kidney and decrease risk of progression disease to dialysis, transplant, or death from kidney disease.
STATEMENT OF DISCLOSURE:
Nelson Chiang and the planners of this activity have no relevant financial relationship(s) with ineligible companies to disclose.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.
AWARD OF CME CREDIT:
CME credit will be granted to participants who attend the conference and complete the evaluation survey.
The Sacramento Valley CME Program is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians. The Sacramento Valley CME Program takes responsibility for the content, quality and scientific integrity of this CME activity.
Credit Designation Statement
The Sacramento Valley CME Program designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses may report 1 hour participation toward the continuing education requirements for license renewal by the California Board of Registered Nurses.
- 1.00 AMA PRA Category 1 Credit(s)™